4 Years of Biotech Relative Outperformance Appears to Have Run its Course
We’ve been bullish on biotech for a long, long time dating back to summer 2012 in posts outlined here and here. Despite many calling for tops in the space for quite some time, I’ve been reticent to do so, outlining…